Eli Lilly and Co - Company Profile
Powered by 
All the sales intelligence you need on Eli Lilly and Co in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Eli Lilly and Co fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Eli Lilly and Co.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Eli Lilly and Co (Lilly) is a pharmaceutical company that discovers, develops, manufactures, and markets human healthcare products. Its major products focus on therapeutic areas such as cardiometabolic health, oncology, immunology, and neuroscience. The company distributes its pharmaceutical health products through independent wholesale distributors through the brands Basaglar, Humalog, Jardiance, Trulicity, Cyramza, and Emgality to wholesalers, pharmacy benefit managers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. The company operates R&D facilities, and production and distribution facilities in North America, South America, Europe, the Middle East, Africa, and Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.
Headquarters
United States of America
Address
Lilly Corporate Ctr, Drop Code 1094, Indianapolis, 46285
Website
www.lilly.com
Telephone
1 317 2762000
No of Employees
50,605
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
LLY (NYSE)
Revenue (2024)
$65.2B
44.7%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
94.9%
(2024 vs 2023)
Market Cap*
$1,143.2B
Net Profit Margin (2024)
XYZ
34.7%
(2024 vs 2023)
* As of and is in US$
Eli Lilly and Co premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Human Pharmaceutical | Basaglar |
| Cardiometabolic Health Products | Humalog |
| Oncology Products | insulin lispro |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In June, Lilly TuneLab signed a partnership with Charles River Laboratories International to allow AI/ML drug discovery models trained on decades of Lilly's proprietary research data. |
| 2026 | Contracts/Agreements | In June, Lilly TuneLab signed a partnership with Axcelead Drug Discovery Partners to promote AI drug discovery. |
| 2026 | Acquisitions/Mergers/Takeovers | In June, the company acquired Centessa Pharmaceuticals plc. |
Competitor Comparison
| Key Parameters | Eli Lilly and Co | Johnson & Johnson | Merck & Co Inc | Pfizer Inc | AbbVie Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Indianapolis | New Brunswick | Rahway | New York City | North Chicago |
| State/Province | Indiana | New Jersey | New Jersey | New York | Illinois |
| No. of Employees | 50,605 | 138,200 | 75,000 | 75,000 | 57,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| David A. Ricks | Chief Executive Officer; Chairman; President | Executive Board | 2017 | 58 |
| Lucas Montarce | Chief Financial Officer; Executive Vice President | Senior Management | 2024 | 48 |
| Diogo Rau | Executive Vice President; Chief Information Officer; Chief Digital Officer | Senior Management | 2021 | 51 |
| Eric Dozier | Chief People Officer; Executive Vice President - Human Resources and Diversity | Senior Management | 2022 | 58 |
| Daniel M. Skovronsky, M.D., Ph.D. | President - Lilly Research Laboratories and Immunology; Executive Vice President; Chief Product Officer; Chief Scientific Officer | Senior Management | 2025 | 52 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer